Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

-The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chain

-Clients to benefit from accelerated timelines, as well as reduced complexity and risk in development and manufacturing

Laupheim and Martinsried/Munich, Germany, December 2, 2025 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

Together, the companies will offer clients seamless, end-to-end solutions from early formulation through to commercial manufacturing, combining their complementary expertise to accelerate product’s path to market. This collaboration responds to the evolving needs of the biologics market, as increasing complexity in modalities and regulatory expectations drive demand for integrated, science-driven solutions. Clients will benefit from a unified interface and aligned project teams, reducing tech transfer risks and enabling faster progression from early development to clinical and commercial stages.

Coriolis Pharma brings a unique combination of in silico and wet lab formulation and drug product development expertise, scientific depth, and advanced analytical capabilities to this collaboration. With a legacy of scientific excellence and commitment to innovation, Coriolis supports every drug development phase from R&D to GMP. The company’s collaborative approach and deep scientific expertise make them a trusted partner from discovery to commercial manufacturing and lifecycle management.

Rentschler Biopharma brings extensive experience in bioprocess development and manufacturing for multiple biotherapeutics, backed by a strong track record of reliability and quality. With a long-standing commitment to client-centric solutions, the company provides robust support from process development through to commercial supply. By focusing on technical excellence, long-term partnerships, and tailored solutions, Rentschler Biopharma ensures successful outcomes at every stage of the project.

Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma, commented: “This marks an important step for both our organizations and for our global clients, and their patients. Coriolis Pharma shares our focus on technical excellence, reliability, as well as our client-centric approach. By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster. This collaboration perfectly exemplifies our vision of advancing medicine to save lives. Together.”

Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma, added: “At Coriolis, we believe that scientific excellence, client-focused innovation, and strong partnerships are key to advancing complex biopharmaceutical programs efficiently and reliably. With Rentschler Biopharma, we have a trusted partner whose process development and manufacturing expertise ideally complements our deep understanding of formulation development and analytical services. This collaboration is a testament to our Coriolis partnering strategy, which fosters synergistic relationships across the biopharma ecosystem. Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success. Our teams look forward to working closely with Rentschler Biopharma on this collaboration.”

The integrated service offering will be available to clients starting December 2025. Both organizations have operations in Germany and the United States, providing global reach and local access for clients in key biopharmaceutical markets.

End of Press Release